The Life Science division of Meridian Bioscience, Inc., a leading global manufacturer of diagnostics and life science raw materials, has officially announced the expansion of its contract services.
According to certain reports, the stated expansion will empower assay developers, working with qPCR, isothermal amplification, or next-generation sequencing (NGS) technologies, to achieve enhanced assay stability, lower limits of detection (LOD), and improved cost efficiencies through Meridian’s advanced enzyme stabilization technologies.
To understand the significance of such an expansion, we must take into account how Meridian is best known for providing end-to-end reagent customization to support a broad range of molecular chemistries.
More on the same would reveal how Meridian brings forth tailored solutions that meet or exceed the evolving demands of global diagnostics industry. This it does using a proprietary glycerol-free enzyme technology and specialized buffer formulations, all of it geared towards providing assay developers with unmatched flexibility, reliability, and performance.
Now, with expanded capabilities, Meridian helps developers in seamlessly transitioning from traditional wet chemistry to ambient temperature-stable assay formats, and that too, without compromising performance.
We get to say so because Meridian’s innovative stabilization solutions, including lyophilization (freeze-drying) and air-drying, are understood to be largely ideal for applications across infectious disease and oncology. You see, these formats, on their part, offer a range of advantages i.e. improved enzyme stability, extended shelf life, elimination of cold-chain logistics, and reduced manufacturing complexity and costs.
Not just that, thanks to ambient temperature-stable formats, the company is able to do away any need to thaw and aliquot reagents, thus simplifying assay workflows, as well as enabling faster implementation and greater ease of use.
Talk about the benefits of Meridian’s expansion bid, we begin from its promise to enhance stability and shelf life. In essence, the company’s expertise should tread up a long distance to extend reagent stability and ensure consistent performance even under challenging storage and transport conditions. Such a mechanism will shrink the customers’ reliance on cold storage.
Next up, there is the prospect of sustaining performance throughout the proceedings. With proven technologies in place, the company should be able to preserve assay’s stability during stabilization of the enzymatic system. Hence, no loss in sensitivity or performance has to be incurred.
Addressing common concerns in regards to enzyme modification, this particular component is understood to be especially critical for applications where detecting low-abundance targets is essential.
Another benefit in play here is rooted in the room for significant cost savings and operational efficiencies. Basically, by transitioning to ambient-temperature-stable reagents, developers can very well reduce cold-chain logistics costs, streamline inventory management, and simplify manufacturing, while simultaneously accelerating time to market for diagnostic assays.
Complementing that would be the company’s comprehensive support at every touchpoint, from concept to commercialization.
Hold on, we still have a few bits left to unpack, considering we haven’t yet touched upon the availability of direct access to enzymology and enzyme stabilization expertise. This opens up the scope for collaborating with Meridian’s scientists to optimize assay protocols, overcome technical challenges, and accelerate product development.
We also haven’t touched upon the potential for leveraging custom formulations and process development. The said feature refers to how Meridian tailors reagent formulations for the purpose of ensuring optimal performance post-stabilization and accommodating unique assay requirements for qPCR, isothermal amplification, and NGS.
Rounding up highlights would be the scalability of Meridian’s manufacturing and supply chain ecosystem, as the company’s vertically integrated supply chain provides access of high-quality enzymes, buffers, and dNTPs to eventually consolidate reagent sourcing and reduce reliance on multiple vendors.
“We have seen a growing demand for reliable, ambient-temperature stable molecular assays,” said Lourdes Weltzien, Ph.D., President – Life Science, Meridian Bioscience. “With our deep expertise in enzyme stabilization technologies, we enable assay developers to enhance stability, improve assay sensitivity, and reduce costs – all while maintaining high performance. Our customized services provide a seamless transition from wet chemistry to ambient temperature stable formats, unlocking new possibilities for molecular diagnostics.”
